

BIOCON GROUP

YTD FY 2010 vs. YTD FY 2009
Q3 FY 2010 vs Q3 FY 2009

FACT SHEET

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
BALANCE SHEET**

(Rs. Crores)

Particulars	As at 31-Dec-09	As at 31-Mar-09
<u>SOURCES OF FUNDS</u>		
Share Capital	100	100
Reserves & Surplus	1,647	1,411
Total Shareholder's Funds	1,747	1,511
Minority interest	31	25
Deferred Tax Liability	48	47
Secured Loans	334	396
Unsecured Loans	132	128
Total Loan Funds	466	524
Total	2,292	2,106
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	1,226	1,221
Intangible Assets	185	163
Investments	384	368
Inventories	415	319
Sundry debtors	396	367
Cash and bank balances	73	12
Loans and advances	127	95
Total Current Assets, Loans & Advances	1,011	792
Less: Current liabilities and provisions	514	438
Net Current assets	497	355
Total	2,292	2,106

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	YTD	YTD	Variance	YTD	YTD	Variance	Full year	Full year
	WITH AXICORP FY 10	WITH AXICORP FY 09		WITHOUT AXICORP FY 10	WITHOUT AXICORP FY 09		ended Mar 31, 2009 WITH AXICORP FY 2009	ended Mar 31, 2009 WITHOUT AXICORP FY 2009
INCOME								
Biopharmaceuticals	1,504	986	53%	846	691	23%	1,384	915
Contract research	207	157	32%	207	157	32%	225	225
Total Sales	1,711	1,142	50%	1,053	847	24%	1,609	1,139
Other income	28	44	-36%	26	42	-38%	65	54
Total Income / Revenues	1,739	1,187	47%	1,079	889	21%	1,673	1,194
EXPENDITURE								
Material & Power Costs	1,008	629	60%	480	385	25%	908	516
Staff costs	168	120	40%	117	97	20%	165	129
Research & Development	59	40	48%	59	40	48%	60	60
Forex Loss/ (gain)	2	16	-89%	1	16	-91%	11	11
Other Expenses	134	104	29%	95	81	16%	141	107
Manufacturing, staff & other exps	1,370	909	51%	751	619	21%	1,285	822
PBDIT /EBIDTA	369	278	33%	327	270	21%	388	372
Interest and finance charges	14	12	18%	12	10	16%	18	15
PBDT	356	266	34%	316	260	21%	370	356
Depreciation	103	80	30%	100	78	28%	110	108
PBT	252	187	35%	216	182	18%	260	248
Taxes	34	13	156%	23	12	102%	12	10
PROFIT FOR THE PERIOD	218	173	26%	192	170	13%	248	238
Add/(less): Minority interest / Share of Losses in Associates	(5)	1		(0)	2		(8)	(5)
Profit before Exceptional Items	213	174	22%	192	172	12%	240	234
Exceptional Item (MTM Provision - Forex) - Net of tax	-	(106)		-	(106)		(147)	(147)
NET PROFIT (PAT)	213	68	212%	192	66	190%	93	87
EPS on issued capital Rs. (before exceptional items)	10.9	8.7		9.6	8.6		12.0	11.7

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceuticals includes licensing income of Rs 30 crores in 9M FY2010, Rs 5.8 crores in 9M FY2009 (both with and without Axicorp);

Previous year's/period's numbers have been reclassified.

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT**

(Rs. Crores)

Particulars	Q3	Q3	Variance	Q3	Q3	Variance	Full year	Full year
	WITH AXICORP FY 10	WITH AXICORP FY 09		WITHOUT AXICORP FY 10	WITHOUT AXICORP FY 09		ended Mar 31, 2009 WITH AXICORP FY 2009	ended Mar 31, 2009 WITHOUT AXICORP FY 2009
INCOME								
Biopharmaceuticals	566	375	51%	307	220	40%	1,384	915
Contract research	69	61	14%	69	61	14%	225	225
Total Sales	635	436	46%	376	281	34%	1,609	1,139
Other income	6	16	-60%	6	15	-62%	65	54
Total Income / Revenues	642	452	42%	382	296	29%	1,673	1,194
EXPENDITURE		-			-			
Material & Power Costs	371	234	58%	166	107	55%	908	516
Staff costs	60	46	30%	42	33	25%	165	129
Research & Development	17	14	26%	17	14	26%	60	60
Forex Loss/ (gain)	10	6	52%	10	6	60%	11	11
Other Expenses	51	41	25%	34	29	16%	141	107
Manufacturing, staff & other exps	508	341	49%	268	189	42%	1,285	822
PBDIT /EBIDTA	133	111	19%	114	107	7%	388	372
Interest and finance charges	3	4	-25%	2	3	-27%	18	15
PBDT	130	108	21%	112	104	8%	370	356
Depreciation	36	27	33%	35	26	32%	110	108
PBT	94	81	17%	77	78	0%	260	248
Taxes	11	6	93%	7	4	61%	12	10
PROFIT FOR THE PERIOD	83	75	11%	71	73	-4%	248	238
Add/(less): Minority interest / Share of Losses in Associates	(2)	(1)		0	(0)		(8)	(5)
Profit before Exceptional Items	81	74	9%	71	73	-3%	240	234
Exceptional Item (MTM Provision - Forex) - Net of tax	-	(46)		-	(46)		(147)	(147)
NET PROFIT (PAT)	81	28	187%	71	27	159%	93	87
EPS on issued capital Rs. (before exceptional items)	4.2	3.8		3.6	3.8		12.0	11.7

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceuticals includes licensing income of Rs 18 crores in Q3 FY2010, Rs 3 crores in Q3 FY2009 (both with and without Axicorp);

Previous year's/period's numbers have been reclassified.